Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02108977 · ClinicalTrials.gov registry record · NA

Evaluation of Videoconferencing Versus Telephone Genetic Counseling

A NA study of Remote Consultation, Teleconsultation and Remote Consultation, Video, sponsored by VA Office of Research and Development.

Completed
Registry status
NA
Development phase
38
Enrollment target
2
Study locations

NCT02108977: Completed NA study of Remote Consultation, Teleconsultation and Remote Consultation, Video, sponsored by VA Office of Research and Development.

NCT02108977 is a NA study of Remote Consultation, Teleconsultation and Remote Consultation, Video that has completed, run by VA Office of Research and Development. The registered enrollment target is 38 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02108977, a NA study of Remote Consultation, Teleconsultation and Remote Consultation, Video, has completed, sponsored by VA Office of Research and Development.

COMPLETED
Registry status
NA
Development phase
38 participants
Enrollment target
2
Study locations

Study Summary

Genetic counseling has benefits for individuals and their family members in their health care decision-making. Provision of genetic counseling has been deemed standard of care by several medical organizations and incorporated into clinical guidelines, such as those of the US Preventive Services Task Force. To better comply with these guidelines, Genomic Medicine Service (GMS) recently established at the Salt Lake City, Utah VA medical center to provide genomic services and counseling as a part of VA Patient Care Services. For Veterans for whom in-person genetic counseling in not feasible, GMS conducts counseling either via telephone or videoconferencing. Although both of these methods can be effective for delivering genetic counseling, each has its relative advantages and disadvantages. The specific aim of this study is to gain a better understanding of the advantages and disadvantages of these two modalities. This information will be useful not only for genetic counseling but also other interventions that use telephone or videoconferencing to access patients.

Primary Outcome

Subjects will be asked 8 True/False genetics-related questions before and after counseling to assess improvement and retention of genetic counseling knowledge and information

Interventions

  • OTHER Videoconferencing Genetic Consultation
  • OTHER Teleconferencing Genetic Consultation

Study Locations (2)

North Carolina

  • Durham VA Medical Center, Durham, NC - Durham

Utah

  • VA Salt Lake City Health Care System, Salt Lake City, UT - Salt Lake City

Trial Details

FieldValue
Enrollment Target 38 participants
Start Date 2014-04
Est. Completion 2015-03
Phase NA
VA Office of Research and Development

1,668 total trials

What the finished NCT02108977 record still lists

NCT02108977 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).

The record links to 2 conditions, with Remote Consultation, Teleconsultation appearing as the primary indexed condition, and to 2 interventions - of which Videoconferencing Genetic Consultation is the first listed.

NCT02108977 reports a single indexed study location in North Carolina, Utah.

Frequently Asked Questions

What is clinical trial NCT02108977 about?

NCT02108977 is a clinical study titled "Evaluation of Videoconferencing Versus Telephone Genetic Counseling". Genetic counseling has benefits for individuals and their family members in their health care decision-making. Provision of genetic counseling has been deemed standard of care by several medical organizations and incorporated into clinical guidelines, such as those of the US Preventive Services Task...

What is the current status of trial NCT02108977?

This trial is currently completed. It is a NA study. The enrollment target is 38 participants. The study started on 2014-04. Estimated completion is 2015-03.

What conditions does trial NCT02108977 study?

This clinical trial studies the following conditions: Remote Consultation, Teleconsultation, Remote Consultation, Video.

What interventions are being tested in trial NCT02108977?

The interventions under investigation include: Videoconferencing Genetic Consultation (OTHER), Teleconferencing Genetic Consultation (OTHER).

Who is sponsoring clinical trial NCT02108977?

This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02108977 being conducted?

This trial has 2 study locations across North Carolina, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

How this trial's enrollment target compares

Where NCT02108977's enrollment target sits among peer trials

38 1538th of 2000 higher than 461 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01684904 · 38 participants · NA

    Proton Therapy for Esophageal Cancer

  • NCT03310879 · 38 participants · Phase 2

    Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6

  • NCT03896269 · 38 participants · Phase 1

    CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

  • NCT04085315 · 38 participants · Phase 1

    Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02108977, the US trial registry maintained by the National Library of Medicine. NCT02108977 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.